Tag Archives: Biogen’s

Despite rough start, Biogen’s Aduhelm should find footing, analysts say. But don’t expect much in 2021

As Biogen’s new Alzheimer’s drug Aduhelm makes headlines nearly every day—many covering the drug’s slower-than-expected uptake—one team of biopharma analysts is lowering its 2021 expectations for the med. Nonetheless, despite the drug sputtering out the gate, the team still sees a multibillion-dollar sales opportunity for the company in Alzheimer’s disease. Writing to investors Wednesday, analysts with RBC Capital Markets… Read More »

‘I don’t like it:’ Biogen’s latest Alzheimer’s ad rouses fresh Aduhelm concerns—and some defense

Maybe you occasionally forget appointments or social events, or lose your train of thought in a conversation. Maybe you’re feeling depressed or overwhelmed when making a decision.  According to a online symptoms quiz from Biogen and Japanese partner Eisai, those are just a handful of signs of mild cognitive impairment (MCI), an early indication of… Read More »